Syros Pharmaceuticals, Inc.
SYRSOTCHealthcare● Active
$0.00
$-0.00(-50.00%)
Market Cap$5366
P/E Ratio—
52W High$0.04
52W Low$0.0001
Syros Pharmaceuticals, Inc. (SYRS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SYRS · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2025Report Date: Mar 26, 2025EPS Actual
-$1.19
Est. -$0.70 · -70.0%
Revenue
—
Fiscal Period
Q1 FY2025
FY ends December
Report Date
Mar 26, 2025
After Market Close
▼ Miss EPS
SYRS reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 29, 2026 | — | — | — | — | — | — |
| ◌ Q3 FY2026 | Jul 29, 2026 | — | — | — | — | — | — |
| ◌ Q1 FY2026 | Mar 25, 2026 | -$0.16 | — | — | — | — | — |
| ◌ Q4 FY2025 | Oct 29, 2025 | — | — | — | — | — | — |
| ◌ Q3 FY2025 | Aug 4, 2025 | — | — | — | — | — | — |
| ◌ Q2 FY2025 | May 20, 2025 | -$0.70 | — | — | — | — | — |
| ▼ Q1 FY2025 | Mar 26, 2025 | -$0.70 | -$1.19 | -70.0% | — | — | — |
| ▲ Q4 FY2024 | Oct 31, 2024 | -$0.76 | -$0.68 | +10.5% | — | $0.00B | — |
Q3 FY2026
Jul 29, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2026
Jul 29, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 25, 2026
EPS Actual
—
EPS Est.
-$0.16
EPS Surpr.
—
Revenue
—
Q4 FY2025
Oct 29, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 4, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
May 20, 2025
EPS Actual
—
EPS Est.
-$0.70
EPS Surpr.
—
Revenue
—
Q1 FY2025
Mar 26, 2025Miss
EPS Actual
-$1.19
EPS Est.
-$0.70
EPS Surpr.
-70.0%
Revenue
—
Q4 FY2024
Oct 31, 2024Beat
EPS Actual
-$0.68
EPS Est.
-$0.76
EPS Surpr.
+10.5%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $-0.16 | $-0.16 | $-0.16 | 1 |
| Q3 FY2025 | $-0.20 | $-0.20 | $-0.20 | 1 |
| Q2 FY2025 | $-0.24 | $-0.24 | $-0.24 | 1 |
| Q1 FY2025 | $-0.38 | $-0.38 | $-0.38 | 2 |
| Q4 FY2024 | $-0.69 | $-0.65 | $-0.60 | 1 |
| Q3 FY2024 | $-0.69 | $-0.68 | $-0.66 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 4 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2025 | Mar 26, 2025 | -70.0% | $0.03 | $0.03 | -6.06% |
| ▲ Q4 FY2024 | Oct 31, 2024 | +10.5% | $2.51 | $2.52 | +0.40% |
| ▲ Q3 FY2024 | Jul 31, 2024 | +11.4% | $6.26 | $6.00 | -4.15% |
| ▲ Q2 FY2024 | May 14, 2024 | +11.2% | $5.06 | $5.43 | +7.31% |
| ▲ Q1 FY2024 | Mar 27, 2024 | +3.3% | $6.25 | $5.84 | -6.56% |
| ▼ Q4 FY2023 | Nov 14, 2023 | -20.5% | $2.69 | $2.72 | +1.12% |
Q1 FY2025-6.06%
Report Date
Mar 26, 2025
EPS Beat/Miss
-70.0%
Price Before
$0.03
Price After
$0.03
Q4 FY2024+0.40%
Report Date
Oct 31, 2024
EPS Beat/Miss
+10.5%
Price Before
$2.51
Price After
$2.52
Q3 FY2024-4.15%
Report Date
Jul 31, 2024
EPS Beat/Miss
+11.4%
Price Before
$6.26
Price After
$6.00
Q2 FY2024+7.31%
Report Date
May 14, 2024
EPS Beat/Miss
+11.2%
Price Before
$5.06
Price After
$5.43
Q1 FY2024-6.56%
Report Date
Mar 27, 2024
EPS Beat/Miss
+3.3%
Price Before
$6.25
Price After
$5.84
Q4 FY2023+1.12%
Report Date
Nov 14, 2023
EPS Beat/Miss
-20.5%
Price Before
$2.69
Price After
$2.72
Avg Beat Reaction-0.75%
Avg Miss Reaction-2.47%
Beat Rate4 / 6 quarters
Largest Move+7.31% (Q2 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SYRS ends December
Syros Pharmaceuticals, Inc. (SYRS) most recently reported earnings on March 26, 2025 for Q1 FY2025, posting EPS of $-1.19 — missing the analyst consensus of $-0.70 by -70.0%. The next SYRS earnings date is expected around September 1, 2026.
Each quarter, investors track SYRS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SYRS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SYRS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SYRS earnings · 5 questionsSyros Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. SYRS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SYRS historically reports after market close (AMC).
SYRS earnings datewhen is SYRS earningsSYRS next earnings datewhen does SYRS report earningsSYRS earnings calendar
▸ Source: FMP · Syros Pharmaceuticals, Inc. SEC filings · US GAAP · Syros Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026